FDA delays approval decision for Exelixis’ tyrosine kinase inhibitor in colorectal cancer

The FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor in combination with Roche’s Tecentriq for the treatment of metastatic colorectal cancer.